A chimeric EBV gp350 220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice - Cell fusion - Document - PDFSEARCH.IO

First Page		Document Content
Immunology Immune system Biotechnology Virus-like particle Monoclonal antibodies Epstein–Barr virus Fusion protein Antibody Infectious mononucleosis Biology Anatomy Viral diseases		A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice Add to Reading List Source URL: www.translational-medicine.com Download Document from Source Website File Size: 1,83 MB Share Document on Facebook

	Biotechnology, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xTqy - View Document
	PDF Document DocID: 1wroO - View Document
	Building A Better Mousetrap: Patenting Biotechnology In The European Community DocID: 1vr7C - View Document
	BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod DocID: 1vq6b - View Document
	Biotechnology Consultation Agency Response Letter BNF DocID: 1vpUZ - View Document